home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407a.zip
/
M9470086.TXT
< prev
next >
Wrap
Text File
|
1994-07-02
|
2KB
|
38 lines
Document 0086
DOCN M9470086
TI Alternating nevirapine and zidovudine treatment of human
immunodeficiency virus type 1-infected persons does not prolong
nevirapine activity.
DT 9409
AU de Jong MD; Loewenthal M; Boucher CA; van der Ende I; Hall D; Schipper
P; Imrie A; Weigel HM; Kauffmann RH; Koster R; et al; Department of
Virology, Academic Medical Centre, University of; Amsterdam,
Netherlands.
SO J Infect Dis. 1994 Jun;169(6):1346-50. Unique Identifier : AIDSLINE
MED/94253598
AB The potential use of an alternating treatment strategy with nevirapine
and zidovudine in prolonging the antiretroviral effects of nevirapine
was evaluated. Ten human immunodeficiency virus type 1 (HIV-1)-infected
p24 antigen-positive persons who had not received prior antiretroviral
therapy were treated for 9-13 weeks with an alternating regimen of 1
week of nevirapine (200 mg/day) and 3 weeks of zidovudine (600 mg/day).
Serum p24 antigen levels declined during the first week of nevirapine
treatment (median, 59%); however, subsequent courses of nevirapine were
characterized by rising p24 antigen levels, while antigen levels
remained stable or declined during zidovudine treatment. Serum beta
2-microglobulin levels and CD4+ cell counts exhibited similar responses.
HIV-1 isolates obtained from 2 patients revealed 40- and 1000-fold
reductions in nevirapine sensitivity after 8 weeks. These findings
demonstrate that alternating treatment with zidovudine and nevirapine
does not prolong the effectiveness of nevirapine and does not prevent
the development of nevirapine resistance.
DE Adolescence Adult Antiviral Agents/*THERAPEUTIC USE Drug Resistance,
Microbial Drug Therapy, Combination Human HIV Core Protein p24/BLOOD
HIV Infections/*DRUG THERAPY HIV-1/*DRUG EFFECTS
Pyridines/*THERAPEUTIC USE Regression Analysis Support, Non-U.S. Gov't
Time Factors Zidovudine/*THERAPEUTIC USE JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).